Cancer Stem Cell News Volume 9.43 | Nov 18 2020

    0
    5







    2020-11-18 | CSCN 9.43


    Cancer Stem Cell News by STEMCELL Technologies
    Vol. 9.43 – 18 November, 2020
    TOP STORY

    CC-90009, a Novel Cereblon E3 Ligase Modulator Targets Acute Myeloid Leukemia Blasts and Leukemia Stem Cells

    Using a genome-wide CRISPR-Cas9 screen for effectors of CC-90009 response, researchers uncovered the ILF2 and ILF3 heterodimeric complex as a novel regulator of cereblon expression. Knockout of ILF2/ILF3 decreased the production of full-length cereblon protein via modulating CRBN mRNA alternative splicing, leading to diminished response to CC-90009.
    [Blood]

    Abstract


    Learn more about cGMP-manufactured StemSpan™-ACF Without Phenol Red for culturing hematopoietic cell therapy products
    PUBLICATIONSRanked by the impact factor of the journal

    Prediction
    of Cancer Stem Cell Fate by Surface-Enhanced Raman Scattering Functionalized Nanoprobes

    Investigators introduced nickel-based functionalized nanoprobe facilitated surface enhanced Raman scattering (SERS) for prediction of cancer dissemination by undertaking CSC-based surveillance. SERS profiling of CSCs of various cell lines was compared with their cancer counterparts for the prediction of prognosis, with statistical significance of single-cell sensitivity.
    [ACS Nano]

    AbstractGraphical Abstract

    Differentiation of Cancer Stem Cells through Nanoparticle Surface Engineering

    Scientists report the integrated use of nanoparticle engineering and hypothesis-free sensing to identify nanoparticles capable of efficient differentiation of CSCs into non-CSC phenotypes.
    [ACS Nano]

    AbstractPress Release

    Hypoxic
    Glioma Stem Cell-Derived Exosomes Containing Linc01060 Promote Progression of Glioma by Regulating the MZF1/C-Myc/HIF-1α

    The authors explored the mechanisms by which lncRNA derived from hypoxic glioma stem cells cause glioma progression. Isolation and identification of the Linc01060 gene, the exosomes containing them, and the proteins from tumor cells regulating the gene allowed for studying the effects of Linc01060 on proliferation and glycometabolism.
    [Cancer Research]

    Abstract

    SCIRT
    lncRNA Restrains Tumorigenesis by Opposing Transcriptional Programs of Tumor-Initiating Cells

    Researchers showed that as breast tumor-initiating cells formed, a decrease in cell-cycle and increase in self-renewal gene expression was coregulated by SOX2 and EZH2, which colocalized at CpG islands.
    [Cancer Research]

    Abstract

    On-Treatment
    Measurements of Circulating Tumor DNA during FOLFOX Therapy in Patients with Colorectal Cancer

    The authors did not observe a spike in circulating tumor (ct) DNA as a sign of a responsive tumor, but instead ctDNA levels initially decreased and remained low in patients with stable disease or partial response.
    [npj Precision Oncology]

    Abstract

    PARK7
    Maintains the Stemness of Glioblastoma Stem Cells by Stabilizing Epidermal Growth Factor Receptor Variant III

    Deregulation of PARK7 has been implicated in the pathogenesis of various human diseases, including cancer. Scientists clarified the effect of PARK7 on stemness and radioresistance of glioblastoma stem cells.
    [Oncogene]

    Abstract

    AMD1
    Is Required for the Maintenance of Leukemic Stem Cells and Promotes Chronic Myeloid Leukemic Growth

    Researchers found that leukemic stem cells were highly differentiated, and leukemia progression was severely impaired in the absence of adenosyl methionine decarboxylase (AMD1) in vivo.
    [Oncogene]

    Abstract

    LncRNA
    NEAT1 Remodels Chromatin to Promote the 5-Fu Resistance by Maintaining Colorectal Cancer Stemness

    The authors observed that lncRNA NEAT1 was associated with 5-fluorouracil (5-Fu) resistance in colorectal cancer. They showed that NEAT1 promoted 5-Fu resistance in colorectal cells.
    [Cell Death & Disease]

    Full Article

    Stroma
    Secreted IL6 Selects for “Stem-Like” Population and Alters Pancreatic Tumor Microenvironment by Reprogramming Metabolic Pathways

    Scientists showed that in pancreatic tumors, the developing stroma increased tumor initiation frequency in pancreatic cancer cells in vivo by enriching for CD133+ aggressive “stem-like” cells.
    [Cell Death & Disease]

    Full Article

    Mimetics of Extra Virgin Olive Oil Phenols with Anti-Cancer Stem Cell Activity

    Researchers used a natural product-inspired drug discovery approach to identify new compounds that phenotypically mimic the anti-CSC activity of oleacein.
    [Aging]

    Abstract

    How have LSCs changed our understanding of myeloid malignancies? Webinar by Dr. Christopher Park, NYU
    REVIEWS

    The
    Evolution of the Cancer Stem Cell State in Glioblastoma – Emerging Insights into the Next-Generation of Functional Interactions

    The authors summarize the current state of CSCs in glioblastoma using key concepts of evolution as a paradigm to describe how the CSC state is subject to alterations of cell intrinsic and extrinsic interactions that shape their evolutionarily trajectory.
    [Neuro-Oncology]

    Abstract
    INDUSTRY AND POLICY NEWS

    PharmaTher Expands Patent Portfolio with Filing of US Patent for Novel Use of Psilocybin to Treat Cancer

    PharmaTher, Inc. has filed a provisional patent application with the US Patent and Trademark Office outlining the potential novel use of psilocybin to treat cancer, which was discovered by panaceAI™, their proprietary psychedelic drug repurposing artificial intelligence platform.
    [PharmaTher, Inc. (GlobeNewswire, Inc.)]

    Press Release

    Innate Pharma Receives Prime Designation from the European Medicines Agency for Lacutamab in Sézary Syndrome

    Innate Pharma SA announced that the European Medicines Agency granted PRIME designation to lacutamab, the company’s proprietary first-in-class anti-KIR3DL2 humanized cytotoxicity-inducing antibody, for the treatment of patients with relapsed or refractory Sézary syndrome who have received at least two prior systemic therapies.
    [Innate Pharma SA]

    Press Release
    FEATURED EVENT

    i-Vaccines 2021: International Vaccines & Virology Conference

    June 10-11, 2021
    London, England, United Kingdom


    > See All Events

    JOB OPPORTUNITIES

    Postdoctoral
    Research Assistant – Glioblastoma

    Queen Mary University of London – London, England, United Kingdom

    Dean and Faculty Positions – Brain Cancer Biology

    Peking University Shenzhen Graduate School – Shenzhen, China

    Postdoctoral Fellow – Melanoma

    NYU Langone Medical Center – New York, New York, United States

    Senior Group Leader – Rare Cancers

    IRCCS Candiolo Cancer Institute – Candiolo, Italy

    Clinical
    Research Associate – Hematology, Oncology, and Bone Marrow Transplantation

    The University of British Columbia – Vancouver, British Columbia, Canada

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Science News Cancer Stem Cell News
    Archives Contact Us
    Cancer Stem Cell News Twitter